Otsuka EU
Manufacturing · United Kingdom · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Wexham Springs Framewood Rd, Slough, Ber...Phone Number
+44 7768337128Website
www.otsuka-europe.comRevenue
$202.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Otsuka EU
Otsuka EU is a company that operates in the Pharmaceuticals industry. It employs 500to999 people and has 100MMto250M of revenue. The company is headquartered in Slough, Berkshire, United Kingdom.Explore more
Otsuka EU Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Otsuka EU your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Otsuka EU has new funding data
Check out if Otsuka EU is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Otsuka EU
Otsuka EU, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Otsuka EU recently announced quarterly report
Click to see if Otsuka EU had a recent Job posting/layoffs
Product Launch: Get notified when Otsuka EU launches new products
Check if Otsuka EU has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Otsuka EU as Masked Content
Find more new buyers
Compare Similar Companies to Otsuka EU
Compare insights from companies similar to Otsuka EU, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Otsuka EU is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Otsuka EU is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Otsuka EU.
Otsuka EU Tech Stack
A closer look at the technologies used by Otsuka EU
Most Recent Scoops
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Mergers & Acquisitions (M&A)
Otsuka EU News & Media
Aripiprazole once-every-two-months long-acting injectable recommended for approval in the EU by the CHMP for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole
Subject to final approval by the European Commission, the drug will be the first once-every-two-months long-acting injectable (LAI) antipsychotic licensed in the EU for adult patients with schizophrenia stabilised with aripiprazole. Windsor, United Kingdom/Valby, Denmark, 29 January, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinioOtsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
LONDON & PLEASANTON, Calif.--(BUSINESS WIRE)--Otsuka Pharmaceutical Europe Ltd. (Otsuka) and Astex Pharmaceuticals, Inc. (Astex) today announce that the European Commission (EC) has approved INAQOVI® (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. The EC decision applies to the European Economic Area (EEA), which includes the EU member states, Iceland,Otsuka Pharmaceuticals Implements Antibody Discovery, and Cell & Gene Therapy Research & Development by Utilizing the Berkeley Lights Beacon(R) Platform
EMERYVILLE, Calif., July 26, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has implemented the use of the Berkeley Lights Beacon® system for antibody discovery, as well as cell and gene therapy and cell line development research. Since acquiring the Beacon Platform in October 2021, Otsuka Pharmaceutical scientists have been developing significant expertise in using the BerkeleyOtsuka Pharmaceuticals Implements Antibody Discovery, and Cell & Gene Therapy Research & Development by Utilizing the Berkeley Lights Beacon® Platform
EMERYVILLE, Calif., July 26, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has implemented the use of the Berkeley Lights Beacon® system for antibody discovery, as well as cell and gene therapy and cell line development research. Since acquiring the Beacon Platform in October 2021, Otsuka Pharmaceutical scientists have been developing significant expertise in using the Berkeley
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Otsuka EU
Sign Up For FreeTo access detailed company insights
Otsuka EU is a company that operates in the Pharmaceuticals industry. It employs 500to999 people and has 100MMto250M of revenue. The company is headquartered in Slough, Berkshire, United Kingdom.... Read More
